Streetbeat News

IMNM

Immunome, Inc.

Industry

Biotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Open

10.02

Mkt cap

624M

Volume

888K

High

10.38

P/E Ratio

-1.26

52-wk high

30.96

Low

9.69

Div yield

N/A

52-wk low

8.97

Immunome, Inc. announced inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

January 02, 2025 | 11:30 pm

Immunome, Inc. announced inducement grants of non-statutory stock options to 15 new employees under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

December 02, 2024 | 11:45 pm

Immunome, Inc. (IMNM) reported a Q3 loss of $0.78 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is a larger loss compared to $0.36 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 11:30 pm

Immunome, Inc. (NASDAQ:IMNM) presented promising preclinical data for its cancer therapy IM-1021 and proprietary ADC payload HC74, showing superior potency and efficacy in preclinical models. An IND submission is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:11 pm

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome (NASDAQ:IMNM) and maintained a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:06 pm

Immunome, Inc. (NASDAQ:IMNM) will present a poster on the preclinical evaluation of its ROR1-targeted antibody drug conjugate, IM-1021, at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:02 pm

In Friday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Allakos, and Unicycive Therapeutics, while Akanda, Dogwood Therapeutics, and Nexalin Technology were among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 8:31 pm

Several healthcare stocks experienced significant price movements in Monday's after-market session. Vincerx Pharma, Oragenics, Avidity Biosciences, Tivic Health Systems, Verrica Pharmaceuticals, and Immunome saw gains, while LogicMark, Trevena, Soligenix, Mainz Biomed, Kairos Pharma, and Cue Biopharma experienced declines.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 8:31 pm

In Tuesday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Inspire Veterinary, CASI Pharmaceuticals, and Shuttle Pharmaceuticals, while Nuwellis, Puma Biotechnology, and Agape ATP were among the losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 8:31 pm

Immunome is set to present a poster with updated results from its RINGSIDE Phase 2 clinical trial of AL102 at the ESMO conference. This development is significant for the company as it showcases progress in their clinical trials.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 11:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.